Drew Moghanaki 🐕 (@drewmoghanaki) 's Twitter Profile
Drew Moghanaki 🐕

@drewmoghanaki

MD, MPH - Lung Cancer Specialist and Professor, David Geffen School of Medicine at UCLA | Co-Director, Lung Precision Oncology Program, VA Greater Los Angeles

ID: 1322269645

linkhttps://www.uclahealth.org/radonc/drew-moghanaki calendar_today02-04-2013 11:09:53

22,22K Tweet

11,11K Followers

1,1K Following

Michael Chuong (@mikechuongmd) 's Twitter Profile Photo

Drew Moghanaki 🐕 Anurag K. Singh Greg Videtic Single fraction SBRT has become routine in my practice for not only lung but routinely abdominal lesions. Even single iso plan 40 Gy x 1 each to multiple liver mets! Very well tolerated. SMART ONE trial results to be presented at ASTRO 👍

Drew Moghanaki 🐕 (@drewmoghanaki) 's Twitter Profile Photo

Following the published results of LAURA (and ADAURA), it simply isn’t acceptable to manage stage III NSCLC without an EGFR biomarker test result. Especially since Durva doesn’t seem to work for EGFRm tumors after CRT. It’s disheartening to learn this is still happening. #radonc

Hongcheng Zhu 祝鸿程 (@drhongchengzhu) 's Twitter Profile Photo

Thanks IASLC International Mentorship Program #WCLC24. It has been such a privilege for me to spend a week in UCLA Health mentored by Drew Moghanaki 🐕 Impressed by excellent MDTs, advanced technologies, and passion for global health. So much to learn, to discuss, & to cooperate.

Thanks <a href="/IASLC/">IASLC</a> International Mentorship Program #WCLC24. It has been such a privilege for me to spend a week in <a href="/UCLAHealth/">UCLA Health</a> mentored by <a href="/DrewMoghanaki/">Drew Moghanaki 🐕</a> Impressed by excellent MDTs, advanced technologies, and passion for global health. So much to learn, to discuss,  &amp; to cooperate.
Drew Moghanaki 🐕 (@drewmoghanaki) 's Twitter Profile Photo

The successful implementation of enterprise-wide lung cancer screening in the VA has broken through the 10% barrier often associated with the percent of new cases diagnosed by LDCT. #WCLC24 vacsp.research.va.gov/CSPEC/Studies/…

The successful implementation of enterprise-wide lung cancer screening in the VA has broken through the 10% barrier often associated with the percent of new cases diagnosed by LDCT. #WCLC24 vacsp.research.va.gov/CSPEC/Studies/…
Drew Moghanaki 🐕 (@drewmoghanaki) 's Twitter Profile Photo

The ESPATUE phase III randomized clinical trial evaluating the benefit of surgery for stage III NSCLC reports no measurable benefits in > 10-year survivors. #radonc #lcsm Cecilia Pompili MD PhD FACS onlinelibrary.wiley.com/doi/full/10.10…

The ESPATUE phase III randomized clinical trial evaluating the benefit of surgery for stage III NSCLC reports no measurable benefits in &gt; 10-year survivors. #radonc #lcsm <a href="/pompili_cecilia/">Cecilia Pompili MD PhD FACS</a> onlinelibrary.wiley.com/doi/full/10.10…
Drew Moghanaki 🐕 (@drewmoghanaki) 's Twitter Profile Photo

Yes, that’s Andreas Rimner getting a white ribbon, written in German, from Heidi Nafman-Onda at #WCLC24. 🇩🇪 #radonc acro2024.eventscribe.net/fsPopup.asp?Pr…

Yes, that’s Andreas Rimner getting a white ribbon, written in German, from <a href="/heidi_onda/">Heidi Nafman-Onda</a> at #WCLC24. 🇩🇪 #radonc acro2024.eventscribe.net/fsPopup.asp?Pr…